[Concordance of tuberculin tests and Interferon gamma release assays in the prison population]. / Concordancia de las pruebas de tuberculina e Interferón gamma en población reclusa.

OBJECTIVE: To study the agreement of Tuberculin Skin Tests (TST) and Interferon Gamma Release Assays (IGRA) when screening tuberculosis infection amongst inmates recently admitted to prison. MATERIALS AND METHODS: Prospective study conducted in a prison during the months of May and June 2009. Inmates without a TB history, with previous TST negatives or without prior TSTs were included. Participants signed an informed consent form and the study was approved by an independent Ethical Committee. TST (positive 10 > or = mm) and IGRA (Quantiferon TB-Gold) were performed and standardized data collection was carried out. The agreement between both tests was analysed using the Kappa index. RESULTS: A total of 181 people were included. 62% were foreign-born, 17% had previous BCG vaccination, 8.4% were IDUs and 4% HIV-infected. Foreign born subjects were more frequently vaccinated and presented less drug use and HIV infection than people born in Spain. (p=0.02, p=0.02 and p=0.01 respectively). TST results were positive in 24% and IGRA in 26%. Both tests were performed in 149 people (82%). Discordant results were observed in 15.8%. Agreement of the Kappa coefficient was 0.6 (CI 0.4-0.7). Agreement was better in the native population (K=0.8) and worse in BCG vaccinated (K=0.4) and foreign-born subjects (K=0.8). CONCLUSION: Overall agreement was moderate and was less amongst vaccinated subjects and those born abroad. Extension of the study could be useful to evaluate which test better predicts the risk of progression to active TB and the cost-benefit of both tests among the prison population.

Concordancia de las pruebas de tuberculina e Interferón gamma en población reclusa / Concordance of tuberculin test and Interferon gamma release assays in the prison population

Objetivo: Estudiar en población penitenciaria la concordancia de la prueba de la tuberculina (PT) y las pruebas de interferón gamma (IFG). Material y Métodos: Estudio prospectivo realizado en una prisión en mayo-junio de 2009. Se estudian los ingresos sin antecedente de tuberculosis (TB) o con PT previa negativa o no realizada. Se realizó IDR de Mantoux (positivo ³ 10 mm) y extracción sanguínea para prueba de IFG (QuantiFERON®-TB Gold). En los infectados, se realizó despistaje de TB. Se pasó un cuestionario y se solicitó consentimiento informado. El estudio fue aprobado por un Comité Ético ajeno a instituciones penitenciarias. La concordancia entre PT e IFG se basó en el índice Kappa. Resultados: Se incluyeron 181 casos. El 62% eran extranjeros, el 17% vacunados por BCG, el 8,4% UDI y el 4% VIH+. En los extranjeros había más vacunados, menos UDI y menos infectados por VIH que en autóctonos (p=0,02, p=0,02, y p=0,01, respectivamente). La PT fue positiva en el 24% y la IFG en el 26%. Hubo información de ambas en 149 (82%) casos. El 15,8% fueron discordantes. El índice Kappa fue de 0,6 (0,4-0,7). La concordancia varió según subgrupos, siendo mayor en autóctonos (kappa= 0,8) y menor en vacunados (kappa=0,4) e inmigrantes (kappa=0,5). Conclusión: La concordancia global fue moderada-buena, pero en vacunados e inmigrantes fue menor. El nivel de discordancia aconseja ampliar el estudio, así como evaluar que prueba predice mejor el riesgo de progresión a TB y el coste-beneficio de ambas en la población reclusa de nuestro país(AU)

Objective: To study the agreement of Tuberculin Skin Tests (TST) and Interferon Gamma Release Assays (IGRA) when screening tuberculosis infection amongst inmates recently admitted to prison. Materials and Methods: Prospective study conducted in a prison during the months of May and June 2009. Inmates without a TB history, with previous TST negatives or without prior TSTs were included. Participants signed an informed consent form and the study was approved by an independent Ethical Committee. TST (positive 10 >= mm) and IGRA (Quantiferon TB-Gold) were performed and standardized data collection was carried out. The agreement between both tests was analysed using the Kappa index. Results: A total of 181 people were included. 62% were foreign-born, 17% had previous BCG vaccination, 8.4% were IDUs and 4% HIV-infected. Foreign born subjects were more frequently vaccinated and presented less drug use and HIV infection than people born in Spain. (p=0.02, p=0.02 and p=0.01 respectively). TST results were positive in 24% and IGRA in 26%. Both tests were performed in 149 people (82%). Discordant results were observed in 15.8%. Agreement of the Kappa coefficient was 0.6 (CI 0.4-0.7). Agreement was better in the native population (K=0.8) and worse in BCG vaccinated (K=0.4) and foreign-born subjects (K=0.8) Conclusion: Overall agreement was moderate and was less amongst vaccinated subjects and those born abroad. Extension of the study could be useful to evaluate which test better predicts the risk of progression to active TB and the cost-benefit of both tests among the prison population(AU)

[Multi-centre study of the prevalence of latent tuberculosis infection amongst inmates in Spanish prisons]. / Estudio multicéntrico de prevalencia de infección tuberculosa latente en los internados en prisiones españolas.

AIMS: To study the prevalence of latent tuberculosis infection (LTBI) amongst inmates in Spanish prisons. MATERIALS AND METHODS: Multi-centre, cross-sectional study; two stage sampling. Socio-demographic, prison and clinical variables were gathered. A univariate, bivariate and multivariate analysis was carried out using logistic regression with the variables that showed statistical significance. The odds ratio was calculated with a confidence interval of 95%. RESULTS: 378 patients. The Mantoux test (PPD) assessable in 90.2% was available. 91.2% men, 37.8% foreigners with average age of 35.9±10.3 years. Average stay in prison: 2 years, 28.7% had been > 5 years in prison. 49.6% entered prison in 2006 or before. 24.5% had a history of intravenous drug use (IDU). 50.4% presented LTBI that was associated with: age > 40 years (63.2 vs 43.8%; CI: 1.39-3.49; OR: 2.20; p=0.001); stay of > 5 years in prison (71.2 vs 41.3%; CI: 2.13-5.75; OR: 3.50; p<0.001); in prison since 2006 or before (58.1 vs 42.6%; CI: 1.22-2.88; OR:1.87; p=0.004); infected with HCV+ (66.3 vs 45.3%; CI:1.40-4.0; OR: 2.37; p=0.001). The logistic regression model confirmed the independent association of LTBI with: a) age > 40 years (OR: 1.76; CI: 1.08-2.87; p=0.024); and length of prison stay > 5 years (OR: 2.50; CI: 1.41-4.43; p=0.002). CONCLUSIONS: The prevalence of LTBI in prison is very high, especially amongst inmates over 40 and those who have been in prison for more than five years. To prevent the risk of progression to tuberculosis, treatment is recommended for those who require it along with the maintenance of control programmes for this pathology.

Estudio multicéntrico de prevalencia de infección tuberculosa latente en los internados en prisiones españolas / Multi-centre study of the prevalence of latent tuberculosis infection amongst inmates in spanish prisons

Objetivo: Estudiar la prevalencia de infección tuberculosa latente (ITL) entre los presos internados en las prisiones españolas. Material y Método: Estudio multicéntrico, observacional y transversal; muestreo por conglomerado bietápico. Se recogieron variables sociodemográficas, penitenciarias y clínico-serológicas. Se realizó análisis univariante, bivariante y multivariante mediante regresión logística con las variables que mostraron significación estadística. Se calculó la odds ratio con intervalo de confianza del 95%. Resultados: 378 pacientes. Se dispuso de intradermorreacción de Mantoux (IDRM) valorable en el 90,2%. 91,2% hombres, 37,8% extranjeros con edad media de 35,9±10,3 años. Mediana de estancia en prisión: 2 años y el 28,7% había estado > 5 años en prisión. El 49,6% ingresó en prisión en 2006 o antes. El 24,5% tenía antecedentes de uso de drogas intravenosas (UDI). El 50,4% presentaba ITL que se asoció a: edad > 40 años (63,2 vs 43,8%; IC: 1,39-3,49; OR: 2,20; p=0,001); haber estado > 5 años en prisión (71,2 vs 41,3%; IC: 2,13-5,75; OR: 3,50; p<0,001); estar en prisión desde 2006 o antes (58,1 vs 42,6%; IC: 1,22-2,88; OR:1,87; p=0,004); estar infectado por el VHC+ (66,3 vs 45,3%; IC:1,40-4,0; OR: 2,37; p=0,001). El modelo de regresión logística confirmó la asociación independiente de la ITL con: a) edad > 40 años (OR:1,76; IC: 1,08-2,87; p=0,024); y b) estancia > 5 años en prisión (OR: 2,50; IC: 1,41-4,43; p=0,002). Conclusiones: La prevalencia de ITL en prisión es muy alta, sobre todo en los mayores de 40 años y los que están más de cinco años en prisión. Para evitar el riesgo de progresión a tuberculosis, se recomienda tratar a los infectados que lo precisen y mantener los programas de control de esta patología(AU)

Aims: To study the prevalence of latent tuberculosis infection (LTBI) amongst inmates in Spanish prisons. Materials and Methods: Multi-centre, cross-sectional study; two stage sampling. Socio-demographic, prison and clinical variables were gathered. A univariate, bivariate and multivariate analysis was carried out using logistic regression with the variables that showed statistical significance. The odds ratio was calculated with a confidence interval of 95%. Results: 378 patients. The Mantoux test (PPD) assessable in 90.2% was available. 91.2% men, 37.8% foreigners with average age of 35.9±10.3 years. Average stay in prison: 2 years, 28.7% had been > 5 years in prison. 49.6% entered prison in 2006 or before. 24.5% had a history of intravenous drug use (IDU). 50.4% presented LTBI that was associated with: age > 40 years (63.2 vs 43.8%; CI: 1.39-3.49; OR: 2.20; p=0.001); stay of > 5 years in prison (71.2 vs 41.3%; CI: 2.13-5.75; OR: 3.50; p<0.001); in prison since 2006 or before (58.1 vs 42.6%; CI: 1.22- 2.88; OR:1.87; p=0.004); infected with HCV+ (66.3 vs 45.3%; CI:1.40-4.0; OR: 2.37; p=0.001). The logistic regression model confirmed the independent association of LTBI with: a) age > 40 years (OR: 1.76; CI: 1.08-2.87; p=0.024); and length of prison stay > 5 years (OR: 2.50; CI: 1.41-4.43; p=0.002). Conclusions: The prevalence of LTBI in prison is very high, especially amongst inmates over 40 and those who have been in prison for more than five years. To prevent the risk of progression to tuberculosis, treatment is recommended for those who require it along with the maintenance of control programmes for this pathology(AU)

Incidencia de la hepatitis crónica por VHC y necesidad de tratamiento en los internados de prisión / Incidence if HCV induced chronic hepatitis and the need for treatment in the prison population

Los estudios realizados en población reclusa muestran porcentajes de infección 16-20 veces superiores a los de la población no penitenciaria, aunque trabajos recientes sugieren que se ha producido una reducción en los últimos años y que la prevalencia de infección por el VHC en la población reclusa probablemente se sitúe en la actualidad en torno al 36%-38%. El VHC comparte con el VIH las mismas vías de contagio y por ello la coinfección VIH-VHC es muy frecuente especialmenteentre los reclusos. En el medio penitenciario, para el seguimiento clínico y terapéutico de esta enfermedad pueden utilizarse los Protocolos de Coordinación entre Servicios Sanitarios Penitenciarios y Hospitales de referencia, editados por la SESP y recientementepremiados por la OMS, y el Documento de Consenso para la Sanidad Penitenciaria (Programa Actualización enel Tratamiento de la Hepatitis C) con el aval científico de las sociedades científicas AEEH, GESIDA y SESP.La dificultad del manejo del tratamiento y la frecuencia e incluso gravedad de posibles efectos adversos, hacen muy recomendable que las decisiones sean adoptadas por un equipo intra-extrapenitenciario de carácter multidisciplinar

Studies carried out amongst prisoners show levels of infection that are 16-20 times higher than amongst the general public, although recent studies indicate that in recent years this number has gone down. Current prevalance of HCV infection amongst prisoners is presently somewhere in the region of 36%-38% of the total prison population. HCV shares the sametransmission routes as HIV and thus HIV-HCV coinfection is common, especially amongst inmates. For clinical and therapeutic follow-up the following tools can be used: the Coordination Protocols between Prison Health Services and Hospitals (Protocolos de Coordinación entre Servicios Sanitarios Penitenciarios y Hospitales de referencia), published by the SESP and a recent WHO award winner; and the Document of Consensus for Prison Health (Program to Update the Treatment of HepatitisC ), (Documento de Consenso para la Sanidad Penitenciaria (Programa Actualización en el Tratamiento de la Hepatitis C) which is backed by scientific societies such as the AEEH, GESIDA and the SESP.The difficulties inherent in the treatment process and the frequency and possible severity of side effects, make it highly recommendable that any decisions be made by a multi-disciplinary team that can function both inside and outside prison (AU)